Showing 2551-2560 of 5833 results for "".
- AAD: Half of Americans Aren't Protecting Themselves from the Sunhttps://practicaldermatology.com/news/aad-half-of-americans-arent-protecting-themselves-from-the-sun/2460018/Most Americans aren’t using sun protection as often as they should be —increasing their risk for skin cancer, including melanoma. In fact, just half of Americans always or almost always protect themselves from the sun when they’re outside, according to a new survey by
- Crown Labs Adds to Portfolio with Acquisition of Keri from GSKhttps://practicaldermatology.com/news/crown-labs-adds-to-portfolio-with-acquisition-of-keri-from-gsk/2460017/Crown Laboratories, Inc. acquired the North American rights for Keri from GlaxoSmithKline (GSK). The acquisition of Keri from GSK marks the sixth product from GSK that Crown has acquired in the past five months. “Acqui
- Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for NMSC Patients Treated with Superficial Radiation Therapyhttps://practicaldermatology.com/news/five-year-retrospective-study-shows-989-percent-cure-rate-for-nmsc-patients-treated-with-superficial-radiation-therapy/2460013/Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma ski
- FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-duobrii-for-treatment-of-plaque-psoriasis/2460009/The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical lotion that contains a unique combination of halobetasol prop
- FDA Approves AbbVie's Skyrizi for Psoriasishttps://practicaldermatology.com/news/fda-approves-abbvies-skyrizi-for-psoriasis/2460007/Skyrizi™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical trials, Skyrizi prod
- Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapyhttps://practicaldermatology.com/news/fibrocell-to-collaborate-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-rdeb-gene-therapy/2460004/Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disord
- AAD Honors Dr. Robert Brodell for Establishing Free Clinic in the Mississippi Deltahttps://practicaldermatology.com/news/aad-honors-dr-robert-brodell-for-establishing-free-clinic-in-the-delta/2459998/Robert T. Brodell, MD, FAAD, is an American Academy of Dermatology (AAD) Patient Care Hero for working with colleagues at the University of Mississippi Medical Center in Oxford to open a dermatology clinic in the Delta — an area of the state that previously did not have a dermatologist for
- National Psoriasis Foundation Elects New Leaders to Board of Directorshttps://practicaldermatology.com/news/national-psoriasis-foundation-elects-new-leaders-to-board-of-directors/2459993/To recognize their dedication in helping people with psoriasis and psoriatic arthritis as volunteers, members, and donors, the National Psoriasis Foundation (NPF) elected Jerry Bagel MD, MS of East Windsor, NJ, Mike Refermat of San Diego, CA, and Jodi Wood
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription
- Get to Know the Dermatology Hall of Fame's 2019 Inaugural Class of Inducteeshttps://practicaldermatology.com/news/meet-the-dermatology-hall-of-fame-2019-inaugural-class-of-inductees/2459984/The 10 individuals inducted into the Dermatology Hall of Fame’s 2019 Inaugural Class are: Albert Bernard Ackerman, M.D., the author of “Histologic Diagnosis of Inflammatory Skin Diseases” and recipient of the American Academy of Dermatology’s Master Dermatologist